Literature DB >> 26151226

Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

Irina A Kirpich1, Luis S Marsano2, Craig J McClain3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases involving hepatic fat accumulation, inflammation with the potential progression to fibrosis and cirrhosis over time. NAFLD is often associated with obesity, insulin resistance, and diabetes. The interactions between the liver and the gut, the so-called "gut-liver axis", play a critical role in NAFLD onset and progression. Compelling evidence links the gut microbiome, intestinal barrier integrity, and NAFLD. The dietary factors may alter the gut microbiota and intestinal barrier function, favoring the occurrence of metabolic endotoxemia and low grade inflammation, thereby contributing to the development of obesity and obesity-associated fatty liver disease. Therapeutic manipulations with prebiotics and probiotics to modulate the gut microbiota and maintain intestinal barrier integrity are potential agents for NAFLD management. This review summarizes the current knowledge regarding the complex interplay between the gut microbiota, intestinal barrier, and dietary factors in NAFLD pathogenesis. The concepts addressed in this review have important clinical implications, although more work needs to be done to understand how dietary factors affect the gut barrier and microbiota, and to comprehend how microbe-derived components may interfere with the host's metabolism contributing to NAFLD development.
Copyright © 2015 The Canadian Society of Clinical Chemists. All rights reserved.

Entities:  

Keywords:  Dietary factors; Gut microbiome; Intestinal barrier; Metabolic endotoxemia; Nonalcoholic fatty liver disease

Mesh:

Year:  2015        PMID: 26151226      PMCID: PMC4558208          DOI: 10.1016/j.clinbiochem.2015.06.023

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  99 in total

1.  Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

Authors:  R Aller; D A De Luis; O Izaola; R Conde; M Gonzalez Sagrado; D Primo; B De La Fuente; J Gonzalez
Journal:  Eur Rev Med Pharmacol Sci       Date:  2011-09       Impact factor: 3.507

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Tannaz Eslamparast; Hossein Poustchi; Farhad Zamani; Maryam Sharafkhah; Reza Malekzadeh; Azita Hekmatdoost
Journal:  Am J Clin Nutr       Date:  2014-01-08       Impact factor: 7.045

4.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

5.  The gut microbiota as an environmental factor that regulates fat storage.

Authors:  Fredrik Bäckhed; Hao Ding; Ting Wang; Lora V Hooper; Gou Young Koh; Andras Nagy; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

6.  Short-chain fatty acids in germfree mice and rats.

Authors:  T Høverstad; T Midtvedt
Journal:  J Nutr       Date:  1986-09       Impact factor: 4.798

7.  High-fat diet determines the composition of the murine gut microbiome independently of obesity.

Authors:  Marie A Hildebrandt; Christian Hoffmann; Scott A Sherrill-Mix; Sue A Keilbaugh; Micah Hamady; Ying-Yu Chen; Rob Knight; Rexford S Ahima; Frederic Bushman; Gary D Wu
Journal:  Gastroenterology       Date:  2009-08-23       Impact factor: 22.682

8.  Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome.

Authors:  Peter J Turnbaugh; Fredrik Bäckhed; Lucinda Fulton; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2008-04-17       Impact factor: 21.023

9.  Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Won; Angel Mei-Ling Chim; Winnie Chiu-Wing Chu; David Ka-Wai Yeung; Kevin Chi-To Li; Henry Lik-Yuen Chan
Journal:  Ann Hepatol       Date:  2013 Mar-Apr       Impact factor: 2.400

10.  Linking long-term dietary patterns with gut microbial enterotypes.

Authors:  Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis
Journal:  Science       Date:  2011-09-01       Impact factor: 47.728

View more
  72 in total

Review 1.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.

Authors:  Natalia Vallianou; Theodora Stratigou; Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-09

2.  Nutrition in Patients With Cirrhosis.

Authors:  Craig J McClain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-08

3.  Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).

Authors:  Cathrin Sellmann; Cheng Jun Jin; Anna Janina Engstler; Jean-Pascal De Bandt; Ina Bergheim
Journal:  Eur J Nutr       Date:  2016-08-05       Impact factor: 5.614

4.  Bile acids as global regulators of hepatic nutrient metabolism.

Authors:  Phillip B Hylemon; Kazuaki Takabe; Mikhail Dozmorov; Masayuki Nagahashi; Huiping Zhou
Journal:  Liver Res       Date:  2017-04-26

Review 5.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

6.  Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial.

Authors:  R B Jones; T L Alderete; A A Martin; B A Geary; D H Hwang; S L Palmer; M I Goran
Journal:  Pediatr Obes       Date:  2018-02-28       Impact factor: 4.000

7.  Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis.

Authors:  Saman Khalesi; David Wayne Johnson; Katrin Campbell; Susan Williams; Andrew Fenning; Sonia Saluja; Christopher Irwin
Journal:  Eur J Nutr       Date:  2017-11-08       Impact factor: 5.614

Review 8.  The Matrisome, Inflammation, and Liver Disease.

Authors:  Christine E Dolin; Gavin E Arteel
Journal:  Semin Liver Dis       Date:  2020-01-07       Impact factor: 6.115

9.  Cranberry extract attenuates hepatic inflammation in high-fat-fed obese mice.

Authors:  Shannon L Glisan; Caroline Ryan; Andrew P Neilson; Joshua D Lambert
Journal:  J Nutr Biochem       Date:  2016-08-04       Impact factor: 6.048

Review 10.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.